otlertuzumab   

GtoPdb Ligand ID: 9951

Synonyms: CD37-SMIP [8] | TRU-016 | TRU016
Compound class: Antibody
Comment: Otlertuzumab (TRU-016) is a monospecific, humanized anti-CD37 antibody-like protein that is being investigated as a clinical therapeutic for various form of lymphoma [4,6-7]. Otlertuzumab was developed using Aptevo's modular ADAPTIRTM platform.
No information available.
Summary of Clinical Use
Preliminary evidence of clinical efficacy in a small number of patients with highly refractory, heavily pretreated B-cell non-Hodgkin lymphoma has been reported [4]- see NCT00614042. A Phase 1b study of TRU-016 plus other biological or small molecule chemotherapeutic drugs (NCT01644253) is under way (May 2018).
Mechanism Of Action and Pharmacodynamic Effects
Otlertuzumab induces apoptosis directly via binding to the CD37 molecule, utilising a mechanism that is caspase-independent [3,8]. Preclinical in vitro and in vivo studies show that otlertuzumab mediates apoptosis and Fc‚Äźdependent cellular toxicity against primary CLL and NHL cells [8].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00614042 Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma Phase 1 Interventional Aptevo Therapeutics
NCT01644253 Phase 1b Safety and Efficacy Study of TRU-016 Phase 1 Interventional Aptevo Therapeutics